Lupin announced that it has received approval for its Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials from the United States Food and Drug Administration (FDA) to market a generic version of Sanofi Genzyme's Hectorol Injection.
Lupin's Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vial is the generic version of Genzyme's Hectorol Injection. It is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.
Doxercalciferol Injection, 4 mcg/2 mL (2 mcg/mL) Multi-dose Vials had annual sales of approximately USD 133 million in the US (IQVIA MAT September 2018).
Shares of LUPIN LTD. was last trading in BSE at Rs.853.45 as compared to the previous close of Rs. 849.4. The total number of shares traded during the day was 67037 in over 1357 trades.
The stock hit an intraday high of Rs. 861 and intraday low of 843.9. The net turnover during the day was Rs. 57113785.